Featured Case Work
Zofran or ondansetron is a potent anti-emetic drug approved by the United States Food and Drug Administration (FDA) for the treatment of severe nausea and vomiting associated with chemotherapy, radiation treatment and surgery. Although the FDA only approved Zofran for use in seriously ill patients, GlaxoSmithKline (GSK) has illegally marketed Zofran “off-label” as a safe and effective treatment for the very common side effect of pregnancy-related nausea or “morning sickness.” It is estimated that 75% of pregnant women will experience some degree of morning sickness.
Defective Hip Implants
The hip joint, scientifically referred to as the acetabulofemoral joint, is the joint between the femur (the thigh bone) and the acetabulum (the hip socket) of the pelvis, and its primary function is to support the weight of the body in both static (i.e., standing) and dynamic (i.e., walking or running) postures. An artificial hip implant is designed to replicate the human anatomy – that is, the relatively simple ball and socket structure of the human hip joint.
Defective Knee Implants
Unhappy with the sales of their NexGen knee implant line, Zimmer Orthopaedics sought to design a “high-flex” knee device which would allow for more flexion than any other knee implant on the market. Zimmer developed the CR-Flex and LPS-Flex devices which the company then aggressively promoted to orthopedic surgeons for use in younger, more active patients. Since 2003, more than 150,000 Zimmer NexGen CR and Zimmer NexGen CR-Flex Porous Femoral implants have been sold in the U.S.
Xarelto is a blood thinner indicated for the prevention of pulmonary embolism, deep vein thrombosis and stroke in patients suffering from atrial fibrillation. Along with Pradaxa and Eliquis, it is part of a class of drugs known as new oral anticoagulants (“NOACs”). These medications have been aggressively marketed as the next generation of blood thinners intended to replace Coumadin (warfarin). Xarelto was first approved by the United States Food and Drug Administration (FDA) in July 2011.